Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for breast cancer
|Not yet recruiting||TROG 16.02 Local HER-O: A Phase II study of local therapy only (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive Breast Cancer||Royal Adelaide Hospital|
|Not yet recruiting||TROG 16.03 CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases||Royal Adelaide Hospital|
|Not Yet Recruiting||TROG 17.05 AZTEC: A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced triple negative breast cancer||Royal Adelaide Hospital|
|Recruiting||Bone Health Improving bone health of cancer survivors – a pilot study of patient activation and resource provision to improve bone health management in primary care setting for patients with breast and prostate cancer||Flinders Medical Centre|
|Recruiting||Cardiometabolic Study (Breast) - A prospective study of the effect of chemotherapy on metabolic and cardiovascular function in women with early stage breast cancer||Flinders Medical Centre|
|Not Yet Recruiting||EarLee - 1 A Phase III, multicentre, randomized, double-blind, placebocontrolled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer||Royal Adelaide Hospital|
|Not Yet Recruiting||EarLee-2 A Phase III, multicentre, randomized, double-blind, placebocontrolled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate risk early breast cancer||Royal Adelaide Hospital|
|Recruiting||ELIMINATE. Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to down-stage large oestrogen receptor positive breast cancer||Flinders Medical Centre|
|Recruiting||OESTROGEN LOWERING INTERVENTION MAY INCREASE NEOADJUVANT THERAPY EFFICACY||Royal Adelaide Hospital|
|Closed||EMBRACA A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease||Flinders Medical Centre|
|Recruiting||A STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR- POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE||Flinders Medical Centre|
|Recruiting||I3Y-MC-JPBZ monarcHER A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer||Ashford Cancer Centre Research|
|Recruiting||I3Y-MC-JPCF monarchE Protocol I3Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer||Ashford Cancer Centre|
|Recruiting||Olympia. A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.||Royal Adelaide Hospital|
|Not yet recruiting||PALLAS PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer||Flinders Medical Centre|
|Recruiting||PENELOPE B - Phase 3 study evaluating Palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor positive HER-2 normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy||Royal Adelaide Hospital|
|Recruiting||PUMA-NER-6201 An Open-Label Study To Characterise The Incidence And Severity Of Diarrhoea In Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib And Intensive Loperamide Prophylaxis||Ashford Cancer Centre Research|